Eyeworld

3 EW NEWS & OPINION New ASCRS president is the medical director of The Eye Institute of Utah R obert J. Cionni, MD, a world-renowned expert in the field of modern cataract surgery and medical director of The Eye Institute of Utah, will assume his role as the 30th president of the American Society of Cataract & Refractive Surgery (ASCRS) in April 2015. He currently serves as ASCRS vice president and will replace the outgoing president, Richard A. Lewis, MD. Dr. Cionni will deliver the incoming president's address on Saturday, April 18, during the ASCRS Opening General Session of the 2015 ASCRS•ASOA Symposium & Congress in San Diego. In a career spanning more than 25 years, Dr. Cionni has pioneered some of the most advanced tech- niques in his field. He is widely published and continues to be an invited speaker at ophthalmic meet- ings worldwide. "ASCRS has been so important in my career development. I am grateful to Robert Osher [MD] for introducing me to this organiza- tion as I came out of residency," Dr. Cionni said. "ASCRS quickly became one of my main avenues for learn- ing about the newest techniques and technologies that now provide im- proved outcomes for my patients. As time went by, ASCRS also provided me tremendous insight into man- aging a practice and navigating the pressures brought on by ever-chang- ing regulations." ASCRS involvement Dr. Cionni has been an ASCRS member since his first year in practice, 1989. Since then, he has presented or instructed at 26 con- secutive ASCRS•ASOA Symposium & Congress meetings. Dr. Cionni served as chairman of the Practice Management Clinical Committee and as a reviewer of the Journal of Cataract & Refractive Surgery (JCRS). In addition to his current role at The Eye Institute of Utah, Dr. Cionni is an adjunct clinical professor in the Department of Ophthalmology and Visual Sciences at the University of Utah's John A. Moran Eye Center. Prior to his time in Utah, he was the medical director of one of the largest ophthalmology practices in the country, the Cincinnati Eye Institute. Concurrent with his active involvement in ASCRS, Dr. Cionni is a board-certified fellow of the American Academy of Ophthal- mology. He is also a member of the American-European Congress of Ophthalmic Surgeons, the Interna- tional Intra-Ocular Implant Club, and the Utah Medical Association. Dr. Cionni is actively involved with the Utah Ophthalmology Society, serving on its education committee, editorial board, and as a reviewer for numerous journals. Background Dr. Cionni received his medical degree at the University of Cincin- nati and completed his residency at the University of Louisville in 1989. Following residency, he completed a fellowship in anterior segment surgery with Dr. Osher at the Cin- cinnati Eye Institute, specializing in complex cataract surgery, lens implants, and refractive surgery. More information on the ASCRS•ASOA Symposium & Con- gress, held from Friday, April 17 to Tuesday, April 21, can be found at Annualmeeting.ascrs.org. EW Contact information Elliott: aelliott@ascrs.org Robert J. Cionni, MD, to be 2015 ASCRS president by Abbie B. Elliott ASCRS•ASOA Communications Manager © 2013 Novartis 9/13 RES13076JAD CAUTION: Federal (USA) law restricts this device to the sale by or on the order of a physician. INDICATIONS: The AcrySof ® IQ ReSTOR ® Posterior Chamber Intraocular Lens (IOL) is intended for primary implantation for the visual correction of aphakia second- ary to removal of a cataractous lens in adult patients with and without presby- opia, who desire near, intermediate and distance vision with increased spectacle independence. The lens is intended to be placed in the capsular bag. WARNING/PRECAUTION: Careful pre- operative evaluation and sound clinical judgment should be used by the surgeon to decide the risk/benefit ratio before im- planting a lens in a patient with any of the conditions described in the Directions for Use labeling. Physicians should target emmetropia, and ensure that IOL centra- tion is achieved. Care should be taken to remove viscoelastic from the eye at the close of surgery. Some patients may experience visual dis- turbances and/or discomfort due to mul- tifocality, especially under dim light con- ditions. Clinical studies with the AcrySof ® ReSTOR ® lens indicated that posterior capsule opacification (PCO), when pres- ent, developed earlier into clinically sig- nificant PCO. Prior to surgery, physicians should provide prospective patients with a copy of the Patient Information Bro- chure available from Alcon for this prod- uct informing them of possible risks and benefits associated with the AcrySof ® IQ ReSTOR ® IOLs. Studies have shown that color vision discrimination is not adversely affected in individuals with the AcrySof ® Natural IOL and normal color vision. The effect on vision of the AcrySof ® Natural IOL in subjects with hereditary color vision de- fects and acquired color vision defects secondary to ocular disease (e.g., glauco- ma, diabetic retinopathy, chronic uveitis, and other retinal or optic nerve diseases) has not been studied. Do not resterilize; do not store over 45° C; use only sterile irrigating solutions such as BSS ® or BSS PLUS ® Sterile Intraocular Irrigating Solu- tions. ATTENTION: Reference the Directions for Use labeling for a complete listing of indi- cations, warnings and precautions. www.AcrySofReSTOR.com March 2015 Richard A. Lewis, MD, ASCRS outgoing president Robert J. Cionni, MD, ASCRS incoming president

• Cover